Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease
Abstract Background A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) pa...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2016-08, Vol.34 (36), p.4327-4334 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4334 |
|---|---|
| container_issue | 36 |
| container_start_page | 4327 |
| container_title | Vaccine |
| container_volume | 34 |
| creator | Souza, Alessandra R Maruyama, Claudia M Sáfadi, Marco Aurélio P Lopes, Marta H Azevedo, Raymundo S Findlow, Helen Bai, Xilian Borrow, Ray Weckx, Lily Y |
| description | Abstract Background A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) patients. The type of vaccine used and booster response were also analyzed. Methods SCD patients ( n = 141) previously immunized with MCC vaccines had blood drawn 2–8 years after the last priming dose. They were distributed according to age at primary immunization into groups: |
| doi_str_mv | 10.1016/j.vaccine.2016.06.072 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811884319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X16305497</els_id><sourcerecordid>1811884319</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-478c3b2b3c53b3731063d998ae09e236f80347265853de8ea78a56d9381b8efc3</originalsourceid><addsrcrecordid>eNqNkk2LFDEQhhtR3HH1JygBL3vpMd9JX5Rl8AsWPKjgLaTT1bPp6UnGpHtl_r1pZ1TYi0JBEXiqUvW-VVXPCV4TTOSrYX1nnfMB1rQ817iEog-qFdGK1VQQ_bBaYSp5zQn-dlE9yXnAGAtGmsfVBVWsEULKVbW7DpNvY3dEB0jZ5wmCA2T7CRLKkOI2xfmANmgPwYdtdNE5OyIXwzBv7QToPATyAblbP3YJAvrhp1uUvduNgByMI-p8BpvhafWot2OGZ-d8WX199_bL5kN98-n9x831Te24JlPNlXaspS1zgrVMMYIl65pGW8ANUCZ7jRlXVAotWAcarNJWyK5hmrQaescuq6tT30OK32fIk9n7vAxiA8Q5G6IJ0ZoXKf4DxQprjiUp6Mt76BDnFMoiv6hGcM5VocSJcinmnKA3h-T3Nh0NwWYxzgzmrJlZjDO4hKKl7sW5-9zuoftT9dupArw5AVCUu_OQTHZ-MavzCdxkuuj_-cXrex3c6IMvfu7gCPnvNiZTg83n5XqW4yGSYcEbxX4CkULAtA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1807954447</pqid></control><display><type>article</type><title>Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Souza, Alessandra R ; Maruyama, Claudia M ; Sáfadi, Marco Aurélio P ; Lopes, Marta H ; Azevedo, Raymundo S ; Findlow, Helen ; Bai, Xilian ; Borrow, Ray ; Weckx, Lily Y</creator><creatorcontrib>Souza, Alessandra R ; Maruyama, Claudia M ; Sáfadi, Marco Aurélio P ; Lopes, Marta H ; Azevedo, Raymundo S ; Findlow, Helen ; Bai, Xilian ; Borrow, Ray ; Weckx, Lily Y</creatorcontrib><description>Abstract Background A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) patients. The type of vaccine used and booster response were also analyzed. Methods SCD patients ( n = 141) previously immunized with MCC vaccines had blood drawn 2–8 years after the last priming dose. They were distributed according to age at primary immunization into groups: <2 years and 2–13 years and evaluated by years since vaccination (2–3, 4–5 and 6–8). Serum bactericidal antibodies with baby rabbit complement (rSBA) and serogroup C-specific IgG concentrations were measured. The correlate of protection was rSBA titer ⩾8. Subjects with rSBA <8 received a booster dose and antibody levels re-evaluated after 4–6 weeks. Results For children primed under 2 years of age rSBA titer ⩾8 was demonstrated in 53.3%, 21.7% and 35.0%, 2–3, 4–5, 6–8 years, respectively, after vaccination, compared with 70.0%, 45.0% and 53.5%, respectively, for individuals primed at ages 2–13 years. rSBA median titers and IgG median levels were higher in the older group. Six to eight years after vaccination the percentage of patients with rSBA titers ⩾8 was significantly higher in the group primed with MCC-TT (78.5%) compared with those primed with MCC-CRM197 [Menjugate® (33.3%) or Meningitec® (35.7%)] ( p = 0.033). After a booster, 98% achieved rSBA titer ⩾8. Conclusion Immunity to meningococcal serogroup C in SCD children declines rapidly after vaccination and is dependent on the age at priming. Booster doses are needed to maintain protection in SCD patients. Persistence of antibodies seems to be longer in individuals primed with MCC-TT vaccine comparing to those immunized with MCC-CRM197.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2016.06.072</identifier><identifier>PMID: 27395566</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescent ; Age ; Allergy and Immunology ; Anemia, Sickle Cell - immunology ; Antibodies, Bacterial - blood ; Child ; Child, Preschool ; Conjugate vaccines ; Female ; Humans ; Immunization ; Immunization, Secondary ; Laboratories ; Male ; Meningococcal infections ; Meningococcal Infections - epidemiology ; Meningococcal Infections - immunology ; Meningococcal Infections - prevention & control ; Meningococcal vaccines ; Meningococcal Vaccines - immunology ; Neisseria meningitidis ; Neisseria meningitidis, Serogroup C - immunology ; Serum Bactericidal Antibody Assay ; Sickle cell disease ; Streptococcus infections ; Time Factors ; Vaccines ; Vaccines, Conjugate - immunology</subject><ispartof>Vaccine, 2016-08, Vol.34 (36), p.4327-4334</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 5, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-478c3b2b3c53b3731063d998ae09e236f80347265853de8ea78a56d9381b8efc3</citedby><cites>FETCH-LOGICAL-c481t-478c3b2b3c53b3731063d998ae09e236f80347265853de8ea78a56d9381b8efc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1807954447?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27395566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Souza, Alessandra R</creatorcontrib><creatorcontrib>Maruyama, Claudia M</creatorcontrib><creatorcontrib>Sáfadi, Marco Aurélio P</creatorcontrib><creatorcontrib>Lopes, Marta H</creatorcontrib><creatorcontrib>Azevedo, Raymundo S</creatorcontrib><creatorcontrib>Findlow, Helen</creatorcontrib><creatorcontrib>Bai, Xilian</creatorcontrib><creatorcontrib>Borrow, Ray</creatorcontrib><creatorcontrib>Weckx, Lily Y</creatorcontrib><title>Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Background A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) patients. The type of vaccine used and booster response were also analyzed. Methods SCD patients ( n = 141) previously immunized with MCC vaccines had blood drawn 2–8 years after the last priming dose. They were distributed according to age at primary immunization into groups: <2 years and 2–13 years and evaluated by years since vaccination (2–3, 4–5 and 6–8). Serum bactericidal antibodies with baby rabbit complement (rSBA) and serogroup C-specific IgG concentrations were measured. The correlate of protection was rSBA titer ⩾8. Subjects with rSBA <8 received a booster dose and antibody levels re-evaluated after 4–6 weeks. Results For children primed under 2 years of age rSBA titer ⩾8 was demonstrated in 53.3%, 21.7% and 35.0%, 2–3, 4–5, 6–8 years, respectively, after vaccination, compared with 70.0%, 45.0% and 53.5%, respectively, for individuals primed at ages 2–13 years. rSBA median titers and IgG median levels were higher in the older group. Six to eight years after vaccination the percentage of patients with rSBA titers ⩾8 was significantly higher in the group primed with MCC-TT (78.5%) compared with those primed with MCC-CRM197 [Menjugate® (33.3%) or Meningitec® (35.7%)] ( p = 0.033). After a booster, 98% achieved rSBA titer ⩾8. Conclusion Immunity to meningococcal serogroup C in SCD children declines rapidly after vaccination and is dependent on the age at priming. Booster doses are needed to maintain protection in SCD patients. Persistence of antibodies seems to be longer in individuals primed with MCC-TT vaccine comparing to those immunized with MCC-CRM197.</description><subject>Adolescent</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Anemia, Sickle Cell - immunology</subject><subject>Antibodies, Bacterial - blood</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Conjugate vaccines</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Laboratories</subject><subject>Male</subject><subject>Meningococcal infections</subject><subject>Meningococcal Infections - epidemiology</subject><subject>Meningococcal Infections - immunology</subject><subject>Meningococcal Infections - prevention & control</subject><subject>Meningococcal vaccines</subject><subject>Meningococcal Vaccines - immunology</subject><subject>Neisseria meningitidis</subject><subject>Neisseria meningitidis, Serogroup C - immunology</subject><subject>Serum Bactericidal Antibody Assay</subject><subject>Sickle cell disease</subject><subject>Streptococcus infections</subject><subject>Time Factors</subject><subject>Vaccines</subject><subject>Vaccines, Conjugate - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkk2LFDEQhhtR3HH1JygBL3vpMd9JX5Rl8AsWPKjgLaTT1bPp6UnGpHtl_r1pZ1TYi0JBEXiqUvW-VVXPCV4TTOSrYX1nnfMB1rQ817iEog-qFdGK1VQQ_bBaYSp5zQn-dlE9yXnAGAtGmsfVBVWsEULKVbW7DpNvY3dEB0jZ5wmCA2T7CRLKkOI2xfmANmgPwYdtdNE5OyIXwzBv7QToPATyAblbP3YJAvrhp1uUvduNgByMI-p8BpvhafWot2OGZ-d8WX199_bL5kN98-n9x831Te24JlPNlXaspS1zgrVMMYIl65pGW8ANUCZ7jRlXVAotWAcarNJWyK5hmrQaescuq6tT30OK32fIk9n7vAxiA8Q5G6IJ0ZoXKf4DxQprjiUp6Mt76BDnFMoiv6hGcM5VocSJcinmnKA3h-T3Nh0NwWYxzgzmrJlZjDO4hKKl7sW5-9zuoftT9dupArw5AVCUu_OQTHZ-MavzCdxkuuj_-cXrex3c6IMvfu7gCPnvNiZTg83n5XqW4yGSYcEbxX4CkULAtA</recordid><startdate>20160805</startdate><enddate>20160805</enddate><creator>Souza, Alessandra R</creator><creator>Maruyama, Claudia M</creator><creator>Sáfadi, Marco Aurélio P</creator><creator>Lopes, Marta H</creator><creator>Azevedo, Raymundo S</creator><creator>Findlow, Helen</creator><creator>Bai, Xilian</creator><creator>Borrow, Ray</creator><creator>Weckx, Lily Y</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U2</scope></search><sort><creationdate>20160805</creationdate><title>Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease</title><author>Souza, Alessandra R ; Maruyama, Claudia M ; Sáfadi, Marco Aurélio P ; Lopes, Marta H ; Azevedo, Raymundo S ; Findlow, Helen ; Bai, Xilian ; Borrow, Ray ; Weckx, Lily Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-478c3b2b3c53b3731063d998ae09e236f80347265853de8ea78a56d9381b8efc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Anemia, Sickle Cell - immunology</topic><topic>Antibodies, Bacterial - blood</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Conjugate vaccines</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Laboratories</topic><topic>Male</topic><topic>Meningococcal infections</topic><topic>Meningococcal Infections - epidemiology</topic><topic>Meningococcal Infections - immunology</topic><topic>Meningococcal Infections - prevention & control</topic><topic>Meningococcal vaccines</topic><topic>Meningococcal Vaccines - immunology</topic><topic>Neisseria meningitidis</topic><topic>Neisseria meningitidis, Serogroup C - immunology</topic><topic>Serum Bactericidal Antibody Assay</topic><topic>Sickle cell disease</topic><topic>Streptococcus infections</topic><topic>Time Factors</topic><topic>Vaccines</topic><topic>Vaccines, Conjugate - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Souza, Alessandra R</creatorcontrib><creatorcontrib>Maruyama, Claudia M</creatorcontrib><creatorcontrib>Sáfadi, Marco Aurélio P</creatorcontrib><creatorcontrib>Lopes, Marta H</creatorcontrib><creatorcontrib>Azevedo, Raymundo S</creatorcontrib><creatorcontrib>Findlow, Helen</creatorcontrib><creatorcontrib>Bai, Xilian</creatorcontrib><creatorcontrib>Borrow, Ray</creatorcontrib><creatorcontrib>Weckx, Lily Y</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Souza, Alessandra R</au><au>Maruyama, Claudia M</au><au>Sáfadi, Marco Aurélio P</au><au>Lopes, Marta H</au><au>Azevedo, Raymundo S</au><au>Findlow, Helen</au><au>Bai, Xilian</au><au>Borrow, Ray</au><au>Weckx, Lily Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2016-08-05</date><risdate>2016</risdate><volume>34</volume><issue>36</issue><spage>4327</spage><epage>4334</epage><pages>4327-4334</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Background A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) patients. The type of vaccine used and booster response were also analyzed. Methods SCD patients ( n = 141) previously immunized with MCC vaccines had blood drawn 2–8 years after the last priming dose. They were distributed according to age at primary immunization into groups: <2 years and 2–13 years and evaluated by years since vaccination (2–3, 4–5 and 6–8). Serum bactericidal antibodies with baby rabbit complement (rSBA) and serogroup C-specific IgG concentrations were measured. The correlate of protection was rSBA titer ⩾8. Subjects with rSBA <8 received a booster dose and antibody levels re-evaluated after 4–6 weeks. Results For children primed under 2 years of age rSBA titer ⩾8 was demonstrated in 53.3%, 21.7% and 35.0%, 2–3, 4–5, 6–8 years, respectively, after vaccination, compared with 70.0%, 45.0% and 53.5%, respectively, for individuals primed at ages 2–13 years. rSBA median titers and IgG median levels were higher in the older group. Six to eight years after vaccination the percentage of patients with rSBA titers ⩾8 was significantly higher in the group primed with MCC-TT (78.5%) compared with those primed with MCC-CRM197 [Menjugate® (33.3%) or Meningitec® (35.7%)] ( p = 0.033). After a booster, 98% achieved rSBA titer ⩾8. Conclusion Immunity to meningococcal serogroup C in SCD children declines rapidly after vaccination and is dependent on the age at priming. Booster doses are needed to maintain protection in SCD patients. Persistence of antibodies seems to be longer in individuals primed with MCC-TT vaccine comparing to those immunized with MCC-CRM197.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27395566</pmid><doi>10.1016/j.vaccine.2016.06.072</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2016-08, Vol.34 (36), p.4327-4334 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811884319 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Adolescent Age Allergy and Immunology Anemia, Sickle Cell - immunology Antibodies, Bacterial - blood Child Child, Preschool Conjugate vaccines Female Humans Immunization Immunization, Secondary Laboratories Male Meningococcal infections Meningococcal Infections - epidemiology Meningococcal Infections - immunology Meningococcal Infections - prevention & control Meningococcal vaccines Meningococcal Vaccines - immunology Neisseria meningitidis Neisseria meningitidis, Serogroup C - immunology Serum Bactericidal Antibody Assay Sickle cell disease Streptococcus infections Time Factors Vaccines Vaccines, Conjugate - immunology |
| title | Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A51%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20persistence%20after%20serogroup%20C%20meningococcal%20conjugate%20vaccine%20in%20children%20with%20sickle%20cell%20disease&rft.jtitle=Vaccine&rft.au=Souza,%20Alessandra%20R&rft.date=2016-08-05&rft.volume=34&rft.issue=36&rft.spage=4327&rft.epage=4334&rft.pages=4327-4334&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2016.06.072&rft_dat=%3Cproquest_cross%3E1811884319%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1807954447&rft_id=info:pmid/27395566&rft_els_id=S0264410X16305497&rfr_iscdi=true |